Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa

NCT05868733 is registered in ClinicalTrials.gov with International AIDS Vaccine Initiative as lead sponsor.

NCT NCT05868733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05868733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of rVSV∆G-LASV-GPC Vaccine in Adults and Children Residing in West Africa
Lead sponsor
International AIDS Vaccine Initiative
Phase
Phase 2
Overall status
Recruiting
Start date
March 6, 2024
Completion date
April 30, 2027
Enrollment
612 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

lassa fever